Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Correlation Between Serum Nesfatin-1 and Human Cartilage Glycoprotein-39 (YKL-40) Levels and Ultrasonographic Findings in Patients With Knee Osteoarthritis, Effect of Platelet Rich Plasma Treatment on Serum YKL-40 and Nesfatin-1 Levels

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06254976
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:56.892943+00:00
Published At
2024-02-23T00:00:00+00:00
Record Updated At
2024-02-23
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Osteoarthritis of Knee", "Degenerative Osteoarthritis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-02-23"
protocolSection.identificationModule.nctId
"NCT06254976"
protocolSection.identificationModule.officialTitle
"Correlation Between Serum Nesfatin-1 and Human Cartilage Glycoprotein-39 (YKL-40) Levels and Ultrasonographic Findings in Patients With Knee Osteoarthritis, Effect of Platelet Rich Plasma Treatment on Serum YKL-40 and Nesfatin-1 Levels"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["NA"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Osteoarthritis of Knee (protocolSection.conditionsModule.conditions)
  • Degenerative Osteoarthritis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.